We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important...
Employment Tribunal decision.
Dstl research shows that using blood products to treat severely injured patients before they reach hospital improves chances of survival.
David Willetts announces £48 million of new investment in biomedical research.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Manufactured by Becton Dickinson (BD) – tubes may contain a hole or be damaged or deformed, potentially causing blood leakage and/or an inadequate blood-to-additive ratio leading to incorrect test results.
Gadolinium-containing contrast agents are associated with a varying degree of risk of nephrogenic systemic fibrosis. See advice below to minimise risk in the following vulnerable groups: patients with renal impairment; patients in the perioperative liver transplantation period; infants, neonates, and...
Erythromycin has been associated with events secondary to QT interval prolongation such as cardiac arrest and ventricular fibrillation. Erythromycin should not be given to patients with a history of QT interval prolongation or ventricular cardiac arrhythmia, including torsades de pointes,...
The Royal Navy are developing a new Multi Role Ocean Surveillance ship (MROSS) to protect our nation against hostile actors and grow our understanding of maritime threats.
First published during the 2019 to 2022 Johnson Conservative government
How MHRA and OxSonics help cancer drugs go the extra mile.
List of field safety notices (FSNs) from medical device manufacturers from 21 to 26 September 2020
Upper Tribunal Administrative Appeals Chamber decision of Judge Poynter on 15 October 2020
Waters around weirs, sluices, locks and pumping stations can be dangerous.
The Yellow Card scheme is the UK’s system for reporting suspected side effects to medicines and adverse events with medical devices run by the Medicines and Healthcare products Regulatory Agency (MHRA).
MHRA supports innovation in anti-cancer drug delivery by providing regulatory advice to OxSonics early on in the process.
Warning as warm temperatures see more people out on the river.
The government is collaborating with pharmaceutical company Novartis to launch a clinical trial for new cholesterol treatment.
First published during the 2015 to 2016 Cameron Conservative government
An exchange of letters between the Paymaster General, The Rt Hon Michael Ellis QC MP, and Sir Robert Francis QC - Terms of Reference for the Infected Blood Compensation Framework Study
How the rules around blood donation will change for some groups of people, following a clinical study with recommendations.
First published during the 2016 to 2019 May Conservative government
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).